PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

This study will enroll 664 patients who had completed induction chemotherapy combined with the PD-1 antibody sintilimab treatment followed by concurrent cisplatin-based chemoradiotherapy (no concurrent sintiliamb). Patients will be randomly divided into two groups. One group will receive 9 cycles of sintilimab therapy, while the other group will receive an additional year of capecitabine chemotherapy on top of the sintilimab treatment. The primary endpoints will be event-free survival and overall survival.

NCT Number	NCT06900218
Lead Sponsor	Sun Yat-sen University
Conditions	Nasopharyngeal Carcinoma (NPC)
Enrollment	664 participants
Start Date	2025-05-01
Primary Completion	2030-05-01 (estimated)
Study Completion	2033-05-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-02